Therefore, although our findings highlight SPON2 as a promising biomarker, direct mechanistic studies in prostate cancer cells are needed to establish whether SPON2 engages PI3K–AKT or Notch pathways in this disease setting (19, 22). The gene discussed is SPON2; the disease is prostate cancer.